This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
ObjectivesRegistered, prospective, multicenter study of the short-term clinical outcomes of a novel transcatheter aortic valve system (Xcor system, Saint Medical Technology, Inc., Nanjing) to evaluate its safety and efficacy.Methods130 high risk patients with symptomatic severe AS from 11 institutions were treated with the novel Xcor system.
Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heart valve, for which more than 1.6 are affected by tricuspid regurgitation, 1 which can severely impact quality of life. Abbott has announced U.S million people in the U.S. are estimated to be affected. the Roger L.
Food and Drug Administration ( FDA ) confirmed 13 to 1, with 0 abstention that the benefits of Abbott's TriClip™ transcatheter edge-to-edge repair (TEER) system outweighed the risks for the treatment of people with tricuspid regurgitation (TR). On the final question of the benefit of TriClip versus the risk, the vote was 13 to 1 in favor.
Eagle looks at sacubitril/valsartan in patients hospitalized with decompensated heart failure, then examines the prevalence and outcomes of patients with discordant high gradient aorticstenosis.
Background Myocardial infarction (MI) has been shown to induce fibrotic remodelling of the mitral and tricuspid valves. It is unknown whether MI also induces pathological remodelling of the aortic valve and alters aorticstenosis (AS) progression. vs –0.04±0.04 cm 2 /m 2 /year; p=0.004).
BACKGROUND:Data concerning the outcomes of transcatheter aortic valve replacement in type 0 bicuspid aorticstenosis (AS) are scarce. Ascending aortic diameter was the single predictor of 1-year mortality in type 0 bicuspid patients (hazard ratio, 1.59 [95% CI, 1.03–2.44];P=0.035). Poverall=0.522; 1 year: 10% versus 2.3%
BACKGROUND:This study aimed to compare the incidence and prognostic implications of new-onset conduction disturbances after surgical aortic valve replacement (SAVR) in patients with bicuspid aortic valve (BAV) aorticstenosis (AS) versus patients with tricuspidaortic valve (TAV) AS (ie, BAV-AS and TAV-AS, respectively).
Objective A novel artificial intelligence-based phenotyping approach to stratify patients with severe aorticstenosis (AS) prior to transcatheter aortic valve replacement (TAVR) has been proposed, based on echocardiographic and haemodynamic data. ±15.8 ±15.1 mm Hg, p value: 0.0079). to 84.7%) and 74.6% (95% CI 65.9%
Standalone performance for significant major valve disease pathology (aorticstenosis and regurgitation and mitral and tricuspid regurgitation) had a 93 percent sensitivity and 93 percent specificity.
Assessment of fluid overload identifies aorticstenosis (AS) patients at high risk and treatment of fluid overload may potentially improve the post-interventional clinical course. TAVI, transcatheter aortic valve implantation. FO by BIS was defined as ≥1.0 L L = euvolaemia).
Tricuspid regurgitation (TR): frequency, clinical presentation, management and outcome among patients with severe left-sided valvular heart disease in Europe. ESC-EORP, European Society of Cardiology-EURObservational Research Programme; TV, tricuspid valve.
Patients with bicuspid aortic valves (BAV) are predisposed to the development of aorticstenosis. We performed a pairwise meta-analysis, comparing the efficacy of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in patients with BAV. to 4.58, p=0.04).
Proposed approach for clinical management and therapeutic optimization in patients with heart failure with reduced ejection fraction and low blood pressure. Low blood pressure with major or mild symptoms. **SBP SBP <80mmHg or symptomatic low BP or asymptomatic low BP.
Procedure trends certainly suggest that we’ve entered the TAVR era, but a pair of new studies show that surgical aortic valve replacement (SAVR) is a far better option for many younger and healthier patients who are increasingly seen as TAVR candidates. Much of these SAVR declines occurred in patients with tricuspidaortic valves (from 84.5%
Objectives This study aimed to evaluate the prognostic value of coronary microvascular dysfunction (CMD) at long term after transcatheter aortic valve implantation (TAVI) and to explore its relationship with extravalvular cardiac damage (EVCD).
Transcatheter valve therapy has evolved from a novel treatment for the sickest patients to become the standard of care for many with aorticstenosis. The rapid adoption of transcatheter mitral and tricuspid therapies has also transformed the treatment landscape, expanding options for patients with structural heart disease.
Transcatheter valve therapy has evolved from a novel treatment for the sickest patients to become the standard of care for many with aorticstenosis. The rapid adoption of transcatheter mitral and tricuspid therapies has also transformed the treatment landscape, expanding options for patients with structural heart disease.
Usual structures imaged in this view are the right ventricular free wall and outflow region, interventricular septum, aorta, and aortic valve, left ventricular outflow tract, anterior and posterior mitral leaflets, left ventricular cavity, posterior wall of left ventricle and left atrium. Apical four chamber view is illustrated here.
Objective CT aortic valve calcium score (AVC score ) and density (AVC density ) thresholds have been recommended for aorticstenosis (AS) severity assessment in tricuspidaortic valve (TAV). We aimed to compare AVC score and AVC density in bicuspid aortic valve (BAV) versus TAV.
Objectives Grading the severity of moderate mixed aorticstenosis and regurgitation (MAVD) is challenging and the disease poorly understood. Methods Moderate MAVD was defined as coexisting moderate aorticstenosis (aortic valve area (AVA) 1.0–1.5 –1.5 –0.6 –1.5 –0.6 to 0.99; p=0.007).
Background Bicuspid aortic valve (BAV) is often associated with a concomitant aortopathy. However, few studies have evaluated the effect of the aortic valve (AV) phenotype on the rate of dilation of the aorta. Doppler echocardiography was performed annually to assess AS severity and measure ascending aorta (AA) dimensions.
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
Program Designations Access and Publications (A&P) 1 Participant User File (PUF) 2 Task Force on Funded Research (TFR) 3 Special Projects 4 Adult Cardiac Surgery Database Lead Author Title Publication Date William Keeling 2 National Trends in Emergency Coronary Artery Bypass Grafting European Journal of Cardiothoracic Surgery October 2023 Jake (..)
This year’s TCT conference saw a deluge of TAVR studies examining everything from the efficacy of valve designs to TAVR’s impact on aortic and tricuspid regurgitation. The TAVR UNLOAD trial also found that there’s not much to gain by performing earlier TAVR in patients with HFrEF and moderate aorticstenosis.
AF, atrial fibrillation; LAVI, left atrial volume index; RA, right atrial; RV, right ventricular; sPAP, systolic pulmonary artery pressure; SVI, stroke volume index; TR, tricuspid regurgitation. Aims Paradoxical low-flow, low-gradient aorticstenosis (pLFLG AS) may represent a diagnostic challenge, and its pathophysiology is complex.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
52 
Let's personalize your content